



FOR IMMEDIATE RELEASE

Stabilitech appoints new Commercial Director

London, 2 February 2011: Stabilitech, the stabilisation company, announced the appointment of Donna Hackett, as Commercial Director with immediate effect. Stabilitech has developed a proprietary technology to stabilise vaccines, biopharmaceuticals and other biological products without the need for refrigeration. Donna will be responsible for the commercialisation of the technology worldwide.

Dr Barbara Domayne-Hayman, CEO of Stabilitech said: "Over the past three years Stabilitech has developed and expanded its technology offering and we have generated great interest in our platform. Donna's appointment will increase the Company's capabilities to commercialise its technology and maximise its value."

Donna has over 20 years of experience in the pharmaceutical industry. She was previously a partner at ProPharma Partners, the international business, pre-, clinical and regulatory consultancy. Prior to this, she headed up the biopharm side of the commercialisation arm of University College London. Before this she was at BTG plc where she was responsible for the commercialisation of the pharmaceutical portfolio.

Donna brings a wealth of experience and a successful track record in partnering, business strategy, legal and intellectual property. She has been involved in a range of deals with small biotech to large pharmaceutical companies in Europe, Japan and USA. Her board memberships have included Helianth Systems and BioVex.

Donna has an Honours degree in Biochemistry from the University of Aberdeen a Diploma in Management Studies and is a qualified, non-practising Barrister.

ENDS

For further information:

Dr Barbara Domayne-Hayman
CEO
Stabilitech Limited
Tel: +44 (0) 7771 635450
Email: bdh@Stabilitech.com

Mary Clark
Capital MSL
Tel: +44 (0) 207 307 5336
Mary.clark@capitalmsl.com



Notes to editors:

Stabilitech's research is focused on new technologies to stabilise vaccines, biopharmaceuticals and other biological products, removing the need for refrigeration. Stabilitech initiated research activities in late 2004. It concluded its first significant funding round in 2007, followed by £3.3m in 2009. The company has been successful in securing non-dilutive funding with awards from the Technology Strategy Board and a \$4m contract from the Defense Threat Reduction Agency (DTRA, part of the US Department of Defense). For more information see www.stabilitech.com